{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:33:54Z","timestamp":1761060834286},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 49-year-old patient with metastatic melanoma was treated with nivolumab (Opdivo). An early <jats:sup>18<\/jats:sup>F-FDG PET\/CT after 2 cycles showed a progressive metabolic disease. A 4-month optimal follow-up <jats:sup>18<\/jats:sup>F-FDG PET\/CT showed a complete metabolic response. The treatment was stopped after 22 cycles because of immunotherapy-related pneumonitis. After discontinuation of treatment, PET\/CT examinations demonstrated a metabolic complete remission during 2 years. The metabolic pattern on early PET was suggestive of pseudoprogression, which is a rare phenomenon reflecting an activation of inflammatory cells within the tumor microenvironment causing lesions to increase in size and to accumulate FDG until a sufficient immune response is developed.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002707","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T12:13:13Z","timestamp":1563192793000},"page":"806-807","source":"Crossref","is-referenced-by-count":10,"title":["Nivolumab-Induced Pneumonitis in Patient With Metastatic Melanoma Showing Complete Remission on 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"44","author":[{"given":"Micheline","family":"Razzouk-Cadet","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Picard","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Grangeon-Chapon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"bib1-20230925","article-title":"Nuclear molecular imaging strategies in immune checkpoint inhibitor therapy","volume":"7","year":"2017","journal-title":"Diagnostics (Basel)"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/RLU.0000000000001934","article-title":"Dynamic adaptation of tumor immune response with nivolumab demonstrated by 18F-FDG PET\/CT","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/RLU.0000000000001673","article-title":"Ipilimumab-induced organizing pneumonia on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti\u2013PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","year":"2017","journal-title":"Front Pharmacol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","article-title":"Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","year":"2014","journal-title":"Nature"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:01:11Z","timestamp":1695621671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002707","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,15]]}}}